Alaunos Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
ALN1003 Preclinical Body Weight Reduction Quarterly-30.5Target: Dose-dependent weight loss and metabolic improvement in IND-enabling studies
Cash and Cash Equivalents Quarterly354KTarget: Secure additional strategic financing or partnership capital to extend runway
Stockholders' Equity Quarterly2.2MTarget: >= 2,500,000 (Nasdaq Listing Rule 5550(b)(1) compliance)
Watch Items
- Nasdaq Delisting RiskTrigger: Failure to regain compliance with the $2.5 million stockholders' equity requirement or alternative listing standardsAction: Submit a compliance plan to Nasdaq, evaluate strategic transactions, or request a hearing before an independent Nasdaq panel to stay delisting.
- Going Concern and Cash RunwayTrigger: Depletion of the remaining cash balance ($0.354 million as of March 31, 2026) without securing new fundingAction: Actively pursue strategic alternatives, including mergers, acquisitions, asset sales, or registered direct offerings.
- ALN1003 IND-Enabling StudiesTrigger: Completion of large animal pharmacokinetic studies and formulation optimizationAction: Transition the lead preclinical candidate ALN1003 into formal IND-enabling studies subject to securing sufficient capital.
Research as of 20 Jun 2026